Welcome to our dedicated page for Achilles Therapeutics plc American Depositary Shares news (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics plc American Depositary Shares stock.
Achilles Therapeutics plc (NASDAQ: ACHL) is a clinical-stage biopharmaceutical company dedicated to developing next-generation, AI-powered precision T-cell therapies for the treatment of solid tumors. The company's innovative approach harnesses the immune system to target and destroy cancer cells by focusing on clonal neoantigens—unique protein markers present on all cancer cells but absent from healthy tissue.
Achilles Therapeutics employs advanced DNA sequencing and its proprietary PELEUS™ bioinformatics platform to identify these clonal neoantigens. This precision allows for the development of tailored T-cell-based product candidates aimed at these specific cancer markers. The company has two ongoing Phase I/IIa clinical trials: CHIRON for advanced non-small cell lung cancer (NSCLC) and THETIS for recurrent or metastatic melanoma.
Recent achievements include the progress in clinical trials, with additional clinical and translational science data expected in the fourth quarter of 2023. The strong cash position of $158.5 million supports operations into mid-2025. The company continues to refine its manufacturing processes, notably the VELOS™ platform, which has significantly improved T-cell doses.
A notable collaboration with Arcturus Therapeutics aims to combine Achilles' AI-driven technology with Arcturus' self-amplifying mRNA platform to develop personalized cancer vaccines. This research highlights Achilles' commitment to leveraging cutting-edge technologies for cancer treatment.
Achilles has also received significant patents and regulatory recognitions, including a US patent for its neoantigen immunogenicity prediction and an Innovation Passport from the UK MHRA, underlining its leadership in the bioinformatics and immunotherapy sectors.
Looking ahead, Achilles plans to report more clinical data in the first quarter of 2024 and continue its focus on optimizing its T-cell therapies and expanding its technological capabilities.
Achilles Therapeutics (NASDAQ: ACHL) announced on April 21, 2023, that it received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement for its American Depositary Shares (ADS). The company has until October 18, 2023, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Despite this notice, Achilles' ADSs will continue to trade on the Nasdaq Global Select Market. The company is actively monitoring its bid price and may consider options to regain compliance. Achilles is developing AI-powered precision T cell therapies for cancer treatments and has ongoing Phase I/IIa trials for patients with advanced non-small cell lung cancer and metastatic melanoma.
Achilles Therapeutics has announced the granting of US patent 11,634,773, which focuses on immunotherapy targeting neoantigens linked to specific HLA alleles preserved in tumors. This patent enables treatment via various modalities such as vaccines and T cell therapies. The proprietary sequence-based method allows identification of HLA loss, crucial for developing effective cancer treatments. This technology is integrated into the company's PELEUS™ bioinformatics platform, facilitating personalized treatment strategies in clinical trials. Achilles, a clinical-stage biopharmaceutical company, is actively working on T cell therapies targeting clonal neoantigens in ongoing trials for advanced non-small cell lung cancer and metastatic melanoma.
Achilles Therapeutics plc (NASDAQ: ACHL) will have its CEO Dr. Iraj Ali and EVP Dr. Ed Samuel participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023, at 11:30 am ET (4:30 pm UK). The event will focus on the company's development of AI-powered precision T cell therapies aimed at treating solid tumors. Achilles is conducting two Phase I/IIa trials: the CHIRON trial for advanced non-small cell lung cancer and the THETIS trial for recurrent or metastatic melanoma. Investors can access a live and archived webcast of the presentation on the company's website under the Events & Presentations section.
The global hospital infection therapeutics market is projected to grow by USD 3,106.6 million from 2022 to 2027, with a CAGR of 4.98%. The market is segmented by drug class (antibiotics, antifungals, antivirals) and infection type (respiratory, surgical, bloodstream, gastrointestinal, urinary). North America is expected to contribute 36% to this growth, driven by increasing chronic disease incidence and higher healthcare spending. Key market players include Abbott, Pfizer, and AstraZeneca, while challenges include stringent regulations affecting R&D.
FAQ
What is the current stock price of Achilles Therapeutics plc American Depositary Shares (ACHL)?
What is the market cap of Achilles Therapeutics plc American Depositary Shares (ACHL)?
What is Achilles Therapeutics plc?
What are clonal neoantigens?
What clinical trials does Achilles Therapeutics currently have ongoing?
What is the PELEUS™ platform?
What recent achievements has Achilles Therapeutics made?
What is the collaboration with Arcturus Therapeutics about?
What is the financial position of Achilles Therapeutics?
What are the future plans for Achilles Therapeutics?
What regulatory recognitions has Achilles Therapeutics received?
How does Achilles Therapeutics leverage AI in its treatments?
